Guizhou Xinbang Pharmaceutical Co., Ltd.
Simbols: 002390.SZ
SHZ
3.89
CNYTirgus cena šodien
32.8887
P/E koeficients
-2.3022
PEG koeficients
7.06B
MRK Cap
- 0.01%
DIV ienesīgums
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 899.2 | 624.6 | 1776.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 3870.6 | 4011.3 | 3466.8 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 1032.7 | 935.7 | 843.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.7 | 4.7 | 4.6 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 5806.2 | 5576.4 | 6091.1 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2671.7 | 2705.9 | 2323.2 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 607.3 | 607.3 | 605.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 204.4 | 217.6 | 219.6 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 811.7 | 825 | 825.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 62.4 | 55.6 | 46.5 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 97.2 | 118.4 | 153.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3986.9 | 4052.3 | 3571 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 977.2 | 993.4 | 788.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1345.8 | 1362.3 | 3382.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 33.3 | 37.4 | 32.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 18.9 | 20.4 | 22.9 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 330.6 | 6.5 | 4.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 41.2 | 45.5 | 23.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 2728 | 2800.1 | 4493.7 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 1943.9 | 2027.2 | 1667.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 373.2 | 271.5 | 28 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 189.6 | 102.7 | 57.3 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 4301.7 | 4218.4 | 3165.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6808.5 | 6619.8 | 4918.3 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 256.6 | 208.7 | 250.2 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | 7065 | 6828.5 | 5168.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 1367.8 | 1387.1 | 3382.5 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 468.6 | 762.5 | 1606.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 268.4 | 374 | 220.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 243.5 | 247.3 | 231.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 31.5 | 6 | -6.4 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -117.1 | -338.6 | 74.8 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 95 | -609.8 | 348.1 | |||||||||||||||||
cash-flows.row.inventory | 0 | -97 | -92.3 | 150.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -108.3 | 372.6 | -430.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 171.3 | 178.4 | 215 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | -295.5 | 566.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -12.4 | -1719.6 | -1516.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 51 | 1523.6 | 1494.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0.5 | 0.9 | 1.7 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -118 | -744.3 | 408 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2019.5 | -4257 | -3561.4 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 86.2 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -86.2 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -168.4 | -230.3 | -197.6 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1998.4 | 3576.7 | 3171.8 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -189.4 | -910.6 | -587.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 2.3 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 283.4 | -1196.9 | 565.2 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 797 | 513.7 | 1710.6 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 513.7 | 1710.6 | 1145.4 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 590.8 | 458 | 742.1 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 432 | 204.2 | 604 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 6350 | 6471.9 | 5845.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 5133.1 | 5119.4 | 4593.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 1217 | 1352.5 | 1252.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 836.4 | 787.1 | 802.1 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5969.5 | 5906.5 | 5395.7 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 13.5 | 14 | 15.4 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 243.5 | 347.7 | 231.6 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 427.8 | 451.5 | 429.9 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 313.4 | 421.1 | 267.5 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 45 | 47.2 | 46.9 | |||||||||||||||||
income-statement-row.row.net-income | 0 | 224.5 | 374 | 173.5 |
Biežāk uzdotie jautājumi
Kas ir Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) kopējie aktīvi?
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) kopējie aktīvi ir 9793091573.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.190.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.334.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.037.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.053.
Kāda ir Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 224479086.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 1367777175.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 836448131.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.